Status:
COMPLETED
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations
Lead Sponsor:
University of Kansas Medical Center
Collaborating Sponsors:
Patient-Centered Outcomes Research Institute
Conditions:
Cryptogenic Sensory Polyneuropathy
Eligibility:
All Genders
30+ years
Phase:
PHASE4
Brief Summary
The purpose of this large comparative effectiveness study led by Richard J. Barohn, MD, of the University of Kansas Medical Center, is to learn about the safety and effectiveness of nortriptyline, dul...
Detailed Description
The goal of this research project is to find the best drug for the treatment of pain in patients with CSPN. While the pharmaceutical industry has focused attention on drugs for treating diabetic senso...
Eligibility Criteria
Inclusion
- Diagnosis of cryptogenic sensory polyneuropathy.
- Likert Pain Score of greater than or equal to 4.
- Must not currently be on nortriptyline, duloxetine, pregabalin or mexiletine or similar class of medication for at least 7 days from baseline study visit.
Exclusion
- Any medical condition or current medication that would prevent them from taking either nortriptyline, duloxetine, pregabalin or mexiletine.
- Unable to give consent.
- Unable or not willing to comply with the study.
- Other causes for polyneuropathy.
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2017
Estimated Enrollment :
402 Patients enrolled
Trial Details
Trial ID
NCT02260388
Start Date
October 1 2014
End Date
September 1 2017
Last Update
July 6 2018
Active Locations (46)
Enter a location and click search to find clinical trials sorted by distance.
1
Barrow Neurological Institute
Phoenix, Arizona, United States, 85013
2
Phoenix Neurological Associates
Phoenix, Arizona, United States, 85018
3
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
4
California Pacific Medical Center
San Francisco, California, United States, 94107